Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Prognostic Factors of Guillain-Barre Syndrome After Intravenous Immunoglobulin or Plasma Exchange?
Neurol 53:598-604, Visser,L.H.,et al, 1999
A 56-Year-Old Woman with New-Onset Hoarsement and Dysphagia
Neurol 104:e213363, McAree,M. & Frontera, J.A., 2025
Natalizumab-Associated PML Identified in the Presymptomatic Phase Using MRI Surveillance
Neurol 78:507-508, Blair,N.F.,et al, 2012
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Guillain-Barre Syndrome
BMJ 337:227-231, Winer,J.B., 2008
Plasmapheresis Improves Outcome in Postinfectious Cerebellitis Induced by Epsteiin-Barr Virus
Neurol 62:1443, Schmahmann,J.D., 2004
Intensive Care of the Myasthenic Patient
Neurol 48 (Suppl 5) :S70-S75997., Mayer,S.A., 1997
Acute Hemorrhagic Leukoencephalitis, A Successful Recovery
Arch Neurol 48:1086-1088, Seales,D.&Greer,M., 1991
Plasmapheresis in Treatment of Human T-Lymphotropic Virus Type-I Associated Myelopathy
Lancet 2:1109-1113, Matsuo,H.,et al, 1988